Skip to main content

Biosimilars

Featured Article

Conference Coverage
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network

Newsfeed

News
10/08/2026
Rebecca Amrick
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a...
10/08/2026
Pharmacy Learning Network
News
10/08/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has...
10/08/2026
Pharmacy Learning Network
News
10/08/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug...
10/08/2026
Pharmacy Learning Network
PharmLaw
10/07/2026
Grace Taylor, MS, MA
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation...
10/07/2026
Pharmacy Learning Network
News
10/01/2026
Rebecca Amrick
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a...
10/01/2026
Pharmacy Learning Network
News
10/01/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
A voluntary Class II recall has...
10/01/2026
Pharmacy Learning Network
News
10/01/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for exenatide injection due to a defective drug delivery system, affecting 5694 pens.
The US Food and Drug Administration (FDA) has issued a Class II recall for exenatide injection due to a defective drug delivery system, affecting 5694 pens.
The US Food and Drug...
10/01/2026
Pharmacy Learning Network
PharmLaw
09/30/2026
Grace Taylor, MS, MA
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Florida is challenging insulin...
09/30/2026
Pharmacy Learning Network
News
09/24/2026
Rebecca Amrick
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection...
09/24/2026
Pharmacy Learning Network
News
09/24/2026
Rebecca Amrick
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has...
09/24/2026
Pharmacy Learning Network

Insights

Interactive Features